🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Pancreatic cancer has a 5-year survival rate of just 3% after it spreads. Read how 12-year pancreatic cancer survivor, Steven Merlin, beat the odds as a result of a personalized medicine plan and participation in a clinical trial in PanCAN : bit.ly/44PIvZm

A study by Yale Cancer Center and Yale School of Medicine shows combining pre- and post-surgery chemotherapy extends pancreatic cancer survival rates, highlighting treatment variability. More in Medical Xpress:  bit.ly/3xHzuVX

Our research related to ENLIGHT-DP is featured in Nature Cancer! In collaboration with ANU Media & National Cancer Institute, the findings show that combining ENLIGHT & DeepPT enhances predictive power for cancer therapies. Read more below.

Video #2 of our short video series is live. Watch to learn more about the technology behind ENLIGHT and how 5x more patients can benefit from precision oncology through the use of our platform.

New study from Sunnybrook Health Sciences Centre and the University of Toronto highlights radioligand therapy involving injecting radioactive isotopes through an IV to target specific cancer cell receptors. Learn more via Medical Xpress: bit.ly/3zzjhTw

Findings from Stanford University and Memorial Sloan Kettering Cancer Center suggest that aging changes lung tissue, potentially suppressing cancer. Learn more via @nature: bit.ly/3Wcl9KO

Thanks @cathshaffer for covering our collaboration with the Sharett Institute of Oncology, Hadassah University and Ultima Genomics in Precision Medicine Online. Together, we aim to improve treatment predictions for solid tumor patients: bit.ly/3Z0jMAP

We’re advancing cancer care in the next phase of the #LiquidBX consortium. With funding from Israel Innovation Authority, we're developing biomarkers for treatment response, leveraging omics data from over 1,000 solid cancer cases. Details in WebWire: webwire.com/ViewPressRel.a…

This week the spotlight lands on our Clinical Operations Manager, Tzivia, whose dedication to precision oncology honors her aunt’s eight-year battle with breast cancer. Her passion for the field makes us very grateful to have her on our team! #PangeaBiomed #PrecisionOncology

Join us as we welcome @NCIKenAldape, Chief of the National Cancer Institute Lab of Pathology, to our scientific advisory board. His insights in molecular neuropathology will help advance our ENLIGHT platform as we aim to drive precision oncology for improved patient care. bit.ly/3ZJ8t04

As a data scientist at Pangea, Doreen (Doreen Ben-Zvi) is driven by the impact our work has on cancer patients. When they respond positively to a recommended treatment, it's a powerful reminder of the change we strive to create. Thank you for all you do!

In the past, we showed how ENLIGHT's predictions can be combined with digital pathology-based expression inference to predict drug response directly from H&E slides. Exciting new results of our collaborators at National Cancer Institute suggest that such predictions can now be spatially refined!

We’re collaborating with OHSU Knight Cancer Institute to support their research on localized, advanced, and metastatic cancers for patients who haven't found success with standard therapies. With cancer rates on the rise, we’re proud to contribute to their efforts: hitconsultant.net/2024/10/24/pan…

Our computational biology researcher, Eden Maimon, is inspired by how far medical solutions have come in the last 50 years. She’s driven to seek new innovations and enhance existing ones, helping push Pangea's mission to identify and advance precision cancer treatments.

What if AI could revolutionize both cancer treatment and drug development? Join our CEO Tuvik Beker at #PMWC2025 to learn how Pangea Biomed's ENLIGHT platform is doing just that. Oncology Applications (Track3), 2/5 at 3:30pm #PrecisionMedicine #Oncology #Biomarkers #AI Precision Medicine World Conference